BD Helps Scientists Advance Immunology and Cancer Research with AI-Powered Insights and Automation

BD (NYSE: BDX) announced the global commercial release of BD Research Cloud 7.0 on January 23, 2026, introducing BD Horizon Panel Maker, an AI-powered tool for automated panel design to support immunology and cancer research.

Rhea-AI Summary

BD (NYSE: BDX) announced the global commercial release of BD Research Cloud 7.0 on January 23, 2026, introducing BD Horizon Panel Maker, an AI-powered tool for automated panel design to support immunology and cancer research.

The cloud-based platform supports collaboration, workflow streamlining and lab operations management, and the new AI tool generates optimized panel recommendations within seconds from custom inputs or curated validated databases. The release highlights integrated visualization features (comparison tables and complexity scores) and explicit support for imaging and spectral panel design with BD FACSDiscover instruments. BD Research Cloud 7.0 is commercially available at bdresearchcloud.com.

Positive

• Global commercial release of BD Research Cloud 7.0 on January 23, 2026
• BD Horizon Panel Maker delivers AI-generated panel recommendations within seconds
• Integrated imaging and spectral panel design support with BD FACSDiscover instruments
• Cloud ecosystem enables collaboration, workflow streamlining, and lab operations management

Negative

• None.

Argus Jan 23 session

-2.06% close to close Open Argus

Details

News Market Reaction – BDX

On Jan 23, the day this news came out, BDX closed 2.06% below the previous close.

Data tracked by StockTitan Argus for the Jan 23 session.

Market Context

This announcement extends BD’s AI roadmap into research workflows, using BD® Research Cloud 7.0 and ...

Analysis

This announcement extends BD’s AI roadmap into research workflows, using BD® Research Cloud 7.0 and BD Horizon™ Panel Maker to streamline flow cytometry panel design. Historically, AI-tagged launches have led to relatively modest one-day moves averaging about 1.03%. In the background, BD reported record fiscal 2025 revenue of $21.8 billion and adjusted EPS of $14.40, while planning a $2.5 billion U.S. manufacturing investment and a Reverse Morris Trust transaction expected to generate about $4 billion in cash.

Key Figures

Record revenue: $21.8 billion GAAP EPS: $5.82 Adjusted EPS: $14.40 +5 more

Record revenue

$21.8 billion

Fiscal 2025 revenue highlighted in DEF 14A

GAAP EPS

$5.82

Fiscal 2025 GAAP EPS in DEF 14A

Adjusted EPS

$14.40

Record adjusted diluted EPS for fiscal 2025

Capital returned

$2.2 billion

Buybacks and dividends in fiscal 2025

Cash from RMT

$4 billion

Expected cash from Waters Reverse Morris Trust transaction

Ownership in new Co

39%

Expected BD shareholder stake in combined life sciences company

U.S. manufacturing plan

$2.5 billion

Planned five-year U.S. manufacturing investments

Equity plan increase

3,935,000 shares

Additional shares for 2004 equity-based compensation plan

Previous AI Reports

2 past events · Latest: Oct 20

Same Type 2 events

1. Oct 20

   AI platform launch

   24h Move

   +1.0%

   Launched BD Incada connected care and AI-enabled Pyxis Pro solutions.

2. Apr 21

   AI monitoring launch

   24h Move

   -1.1%

   Introduced HemoSphere Alta with AI-driven hemodynamic decision support.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

flow cytometry, spectral panel design

2 terms

flow cytometry medical

"provides scientists with a cloud-based ecosystem for flow cytometry that supports"

A laboratory method that uses lasers and sensors to count and analyze individual cells or tiny particles as they flow past a detector, like a high‑speed supermarket scanner that reads barcodes on each item. Investors care because flow cytometry is widely used in drug development, diagnostics and manufacturing quality control; demand for the instruments, reagents and services can signal progress in clinical programs, recurring revenue streams and adoption of new therapies or tests.

spectral panel design technical

"supports integrated imaging and spectral panel design when working with BD"

Spectral panel design is the process of selecting and arranging a set of measurable signals or markers so they can be detected together without confusion, often used in diagnostic tests that read overlapping colors or signals. For investors, good design means a test or instrument can measure more targets accurately and efficiently—like arranging a painter’s palette so colors don’t muddy—leading to better product performance, lower costs, and stronger market competitiveness.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Newest version of BD® Research Cloud features an AI-powered tool for automated panel design to improve quality, efficiency and usability of scientific results across research areas

FRANKLIN LAKES, N.J., Jan. 23, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the global commercial release of BD® Research Cloud 7.0, furthering the company's AI roadmap while strengthening its leadership in flow cytometry and life sciences research. The new release introduces BD Horizon™ Panel Maker, an AI-powered tool for automated panel design – one of the most critical steps across immunology and cancer research experiments designed to help ensure the quality and usability of scientific results.

BD® Research Cloud version 7.0 provides scientists with a cloud-based ecosystem for flow cytometry that supports collaboration between team members, streamlines workflows, and manages laboratory operations, from instrument health to purchasing and managing reagents.

The new BD Horizon™ Panel Maker tool leverages a novel, sophisticated AI algorithm to generate optimized panel recommendations within seconds. Researchers can create panels using custom experimental inputs or draw from curated databases of validated options. Poorly designed panels can lead to unusable, unreliable or irreproducible data, resulting in wasted time, samples, and reagents. By providing automated recommendations and integrated visualization tools, like comparison tables and complexity scores, BD Horizon™ Panel Maker enables researchers to more efficiently evaluate and select the panels best suited for their experiments.

"By harnessing the power of AI, the new version of BD^® Research Cloud is engineered to help scientists reach high-quality scientific insights in a fraction of the time, while reducing complexity and potential for error," said Steve Conly, worldwide president, BD Biosciences. "This new AI tool also unlocks the full potential of our BD FACSDiscover™ Cell Analyzer and Cell Sorters, letting researchers get the most out of both cutting-edge hardware and software, for even the most complex experiments."

BD Horizon™ Panel Maker is the only commercially available tool that supports integrated imaging and spectral panel design when working with BD FACSDiscover™ Instruments.

BD® Research Cloud version 7.0 with BD Horizon™ Panel Maker is now available at bdresearchcloud.com. More information is available at bdbiosciences.com.

About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson. 

Contacts:
Media:	Investors:
Fallon McLoughlin	Adam Reiffe
Director, Public Relations	VP, Investor Relations
201.258.0361	201.847.6927
fallon.mcloughlin@bd.com	adam.reiffe@bd.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/bd-helps-scientists-advance-immunology-and-cancer-research-with-ai-powered-insights-and-automation-302668624.html

SOURCE BD (Becton, Dickinson and Company)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BD (BDX) announce on January 23, 2026 about BD Research Cloud 7.0?

BD announced the global commercial release of BD Research Cloud 7.0 and the AI-powered BD Horizon Panel Maker for automated panel design.

How does BD Horizon Panel Maker speed up panel design for researchers using BDX products?

The tool uses a sophisticated AI algorithm to generate optimized panel recommendations within seconds from custom inputs or curated validated databases.

Does BD Research Cloud 7.0 support BD FACSDiscover instruments for imaging and spectral panel design?

Yes. BD Horizon Panel Maker supports integrated imaging and spectral panel design when used with BD FACSDiscover instruments.

Where can researchers access BD Research Cloud 7.0 and BD Horizon Panel Maker?

BD Research Cloud 7.0 with BD Horizon Panel Maker is available at bdresearchcloud.com; more information is at bdbiosciences.com.

What laboratory functions does BD Research Cloud 7.0 manage for life sciences teams?

The platform supports collaboration, streamlines workflows, and helps manage instrument health, purchasing, and reagent management.